drugset
Drugs / QVM149
last change Jul 2020 re-read 2 minutes ago

QVM149

Developed for
asthma
Investigated by
Novartis Pharmaceuticals

Trials 2 · a red edge is where a trial was stopped

today NCT03108027 · Ph 2 NCT03100825 · Ph 3
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03108027 Jun 2017 → Feb 2018 asthma Novartis Pharmaceuticals Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03100825 Apr 2017 → Sep 2018 asthma Novartis Pharmaceuticals Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03063086 Comparator Jan 2017 → Aug 2018 asthma Novartis Pharmaceuticals Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2020-07-10 Novartis Pharmaceuticals Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma novartis.com ↗
2020-06-05 Novartis Pharmaceuticals Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma novartis.com ↗
2020-05-01 Novartis Pharmaceuticals Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma novartis.com ↗
2019-09-30 Novartis Pharmaceuticals Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma novartis.com ↗
2019-05-22 Novartis Pharmaceuticals Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment novartis.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as QVM149 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03100825 ↗
2

NCT03063086 ↗

NCT03108027 ↗
Route Inhaled “QVM149 150/50/160 μg once daily, delivered as powder in hard capsules via Concept1 inhaler” NCT03100825 ↗